These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20379051)

  • 1. Manageability of acute severe heart failure complicated with left ventricular thrombosis during therapy for breast cancer.
    Szmit S; Kurzyna M; Glówczynska R; Grabowski M; Kober J; Czerniawska J; Filipiak KJ; Opolski G; Szczylik C
    Int Heart J; 2010 Mar; 51(2):141-5. PubMed ID: 20379051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.
    Sengupta PP; Northfelt DW; Gentile F; Zamorano JL; Khandheria BK
    Mayo Clin Proc; 2008 Feb; 83(2):197-203. PubMed ID: 18241629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of trastuzumab-related cardiac dysfunction.
    Carver JR
    Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure.
    Walji N; Bhatt L; Dhallu S; Fernando IN
    Breast; 2008 Aug; 17(4):423-5. PubMed ID: 18479923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
    J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab.
    Martins SJ; Modesto Dos Santos V; Thommen Teles L; Alves Leite V
    Rev Med Chil; 2012 Jun; 140(6):763-6. PubMed ID: 23282614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
    Perez EA
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.
    Ho E; Brown A; Barrett P; Morgan RB; King G; Kennedy MJ; Murphy RT
    Heart; 2010 May; 96(9):701-7. PubMed ID: 20424152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
    Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
    Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of left ventricular assist device application for chemotherapy-related cardiomyopathy caused by trastuzumab and anthracycline.
    Inui T; Kohno H; Matsuura K; Ueda H; Tamura Y; Watanabe M; Inage Y; Yakita Y; Matsumiya G
    J Artif Organs; 2020 Sep; 23(3):270-274. PubMed ID: 31897739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
    Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
    Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
    Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
    J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
    Ewer MS; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Jun; 7(8):600-7. PubMed ID: 17592672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.